The market size of the global hypoglycemic drugs exceeded USD 40 billion in 2017, which became the second largest drug market next only to the oncology drug market. From the distribution of the top 15 varieties by sales on the hypoglycemic drug market, we can see the current product pattern: insulin accounts for more than half of the shares, followed by DPP-4 inhibitors, GLP-1 analogues, and SGLT-2 inhibitors
|
2017年全球降糖药物销售排行榜TOP15分布
胰岛素 DPP-4抑制剂 GLP-1类似物 SGLT-2抑制剂 |
Distribution of Global Top 15 Hypoglycemic Drugs by Sales in 2017 Insulin DPP-4 inhibitors GLP-1 analogues SGLT-2 inhibitors |
Structure of use of hypoglycemic drugs inside and outside China
According to PDB data, the sales of diabetes drugs in sample hospitals of China were RMB 5.76 billion in 2017, wherein, the oral hypoglycemic drugs accounted for 56%, with the top 3 varieties by sales of oral hypoglycemic drugs being acarbose, metformin, and glimepiride.
|
2017年国内口服降糖药物市场占比
阿卡波糖 二甲双胍 格列美脲 其他 |
Market Shares of Oral Hypoglycemic Drugs in China in 2017 Acarbose Metformi Glimepiride Others |
The oral hypoglycemic drugs in China are mainly those three drugs, while on the overseas mature markets, besides those three drugs, the DPP-4 and SGLT-2 inhibitors that are used the most have preliminarily completed substitution of the early varieties, showing that the drug use structure of hypoglycemic drugs in China is significantly different from that of overseas mature markets; in terms of the hypoglycemic drugs for injection, China is based on recombinant human insulin, compared to the GLP-1 analogues, insulin analogues, and the new-generation ultra-long-acting insulin, etc. that rapidly grow in overseas clinical application.
|
Structure of hypoglycemic drugs |
Chinese market |
Overseas mature markets |
|
Oral hypoglycemic drugs |
Based on metformin, acarbose, and glimepiride, etc. |
Metformin, acarbose, glimepiride, DPP-4 inhibitors, SGLT-2 inhibitors |
|
Hypoglycemic drugs for injection |
Based on recombinant human insulin |
Based on insulin analogues and the new-generation ultra-long-acting insulin |
Up-rising star: SGLT-2 inhibitors accounting for one third of the global market
On the global oral hypoglycemic drug market, DPP-4 inhibitors are one of the main drugs, with market share second only to that of metformin. Compared to DPP-4 inhibitors, the up-rising star SGLT-2 inhibitors have the same hypoglycemic effect, and more importantly, the unique cardiovascular benefits and weight losing advantage of SGLT-2 inhibitors enable such drugs to be quite favored by the drug regulators and clinical trials in recent years.
In particular, reducing cardiovascular risk has become one of FDA’s important standards for review of hypoglycemic drugs in recent years, and the therapeutic advantages of SGLT-2 inhib...
(All Rights Reserved)